Form 4: Tevogen Bio CEO Sells Over 1.4 Million Shares in Direct Transaction

Tevogen Bio Holdings Inc. CEO, Director, and 10% Owner Ryan H. Saadi reported the sale of 1,438,206 shares of common stock on June 9, 2025, at a weighted average price of $1.23 per share.

Summary

• Ryan H. Saadi, the Chief Executive Officer, Director, and a 10% owner of Tevogen Bio Holdings Inc. (TVGN), executed a sale of common stock.
• The transaction involved the direct disposition of 1,438,206 shares of Tevogen Bio common stock.
• The sale occurred on June 9, 2025, at a weighted average price of $1.23 per share, with individual transaction prices ranging from $1.10 to $1.425.
• Following this transaction, Mr. Saadi directly beneficially owns 116,814,453.322 shares of common stock.
• Additionally, Mr. Saadi indirectly beneficially owns 193,924 shares through his wife, bringing his total beneficial ownership to 117,008,377.322 shares.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant insider sale by the CEO, which can be interpreted as a bearish signal for the company's stock.

Negatives

• The sale of over 1.4 million shares by the CEO, Director, and a significant owner (10%) could be interpreted negatively by the market, potentially signaling a lack of confidence in the company's near-term prospects or a need for personal liquidity.
• Insider selling, especially by top executives, often raises concerns among investors about the company's future performance.

Risks

• Potential negative investor sentiment and stock price reaction due to the significant insider sale.
• Increased scrutiny from analysts and investors regarding the company's valuation and future outlook following the CEO's share disposition.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider sales, particularly by a company's CEO, are closely watched by the market as they can provide insights into management's perception of the company's value and future prospects. While such sales can be for personal financial planning, a significant disposition may lead to speculation about the company's outlook compared to broader industry trends.

Related Party Transactions

• The document notes indirect beneficial ownership of 193,924 shares by the reporting person's wife.

Stakeholder Impact

• Shareholders may react negatively to the news of the CEO's share sale, potentially leading to a decrease in stock price due to concerns about insider confidence.

Key Dates

Recommendation

Keywords

Tevogen Bio Holdings Inc., TVGN, SEC Form 4, Insider Trading, Stock Sale, CEO, Beneficial Ownership, Ryan H. Saadi, Common Stock